Hangzhou Valgen Medtech Co., Ltd. Overview
Pro stress-test →Hangzhou Valgen Medtech is dedicated to the interventional treatment of structural heart diseases. Founded in 2015 in Hangzhou, the company has applied for more than 500 patents worldwide by the end of 2023. The company employs more than 280 researchers, medical specialists, technicians, and manufacturing workers throughout China.
Strategic Profile
Pro stress-test →Valgen Medtech specializes in interventional treatment products for mitral and tricuspid valve repair, offering solutions including transcatheter mitral valve repair systems, radiation protection screens, balloon dilation catheters, and septal puncture systems. In November 2023, Venus MedTech and Valgen Medtech reached a consensus on signing a letter of intent for exclusive cooperation on strategic marketing for the DragonFly™ Transcatheter Mitral Valve Repair System.
Competitive Landscape
Pro stress-test →Valgen Medtech competes in interventional treatment for mitral and tricuspid valve repair within the medical device industry. Primary competitors include established global medtech companies with transcatheter valve repair platforms (Abbott, Boston Scientific) and emerging Chinese competitors in interventional cardiology. Valgen's competitive advantage lies in its DragonFly™ platform's innovative design and successful regulatory approval in China's high-growth healthcare market.
Industry Context
Hangzhou Valgen Medtech Co., Ltd. operates in Transcatheter valve repair devices.
Key facts
Founded: 2015 · Headquarters: Hangzhou, China · Employees: 280+